ABSTRACT Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg daily. In 12 patients the underlying lesion was malignant. The serum sodium returned to normal (> 135 mmol/l) in all patients after a mean of 8-6 days (SD+5-3 days). Blood urea rose significantly from the pretreatment level of 4-2±2-3 mmol/l to 10-1±5-1 mmol/l at ten days (p<0 001). The average maximum blood urea was 13-4-6-8 mmol/l. In four patients the urea rose above 20 mmol/l, and in two of these demecyocycline was discontinued because of this rise. The azotaemia could be attributed to a combination of increased urea production and a mild specific drug-induced nephrotoxicity. Discontinuation of demeclocycline in six patients led to a fall in serum sodium, in one case precipitously, and return of the urea towards normal levels. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH, and the azotaemia that occurs is reversible and probably dose dependent.
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) has become increasingly recognised as a treatable cause of stupor and confusion in patients with a wide variety of diseases (De Troyer and Demanet, 1976) . Until recently treatment has been directed at correcting the electrolyte abnormalities by fluid restriction, which may be difficult in a confused patient (Perks et al, 1976) , or treatment of the primary condition. Several case reports (Cherrill et al, 1975; De Troyer and Demanet, 1975; Perks et al, 1976; Perks et al, 1978) have suggested that demeclocycline is effective in SIADH. Demeclocycline interferes with the action of antidiuretic hormone on the renal collecting ducts and thus induces nephrogenic diabetes insipidus (Singer and Rotenberg, 1973) . Recent publications (De Troyer, 1977; Forrest et al, 1978) have recorded the efficacy of demeclocycline in correcting hyponatraemia in SIADH. Impaired renal function has been reported in one patient during treatment (De Troyer, 1977 and creatinine (P<0-05) at ten days in patients treated with demeclocycline, although the rise in the former was disproportionately greater. In the six patients in whom the demeclocycline was discontinued the blood urea and creatinine returned towards normal (P<0-005 and P<001 respectively). In four patients the blood urea rose above 20 mmol/l (normal range 2-5-58 mmol/l) on treatment and in a further four patients above 10 mmol/l. This azotaemia led to stopping demeclocycline in two patients. There was no significant relation between the rise in blood urea and the fluid intake in the nine patients in whom adequate data were available, and no change occurred in packed cell volume (PCV) . There was a significant rise (P<0 01) in 24-hour urinary urea excretion on demeclocycline. Serial measurements of creatinine clearance in two patients (4 and 14) showed a progressive fall from 98 ml/min to 84 ml/min and from 40 ml/min to 24 ml/min respectively.
Discussion
In the 14 patients with SIADH the serum sodium returned to normal during treatment with demeclocycline, confirming the observations of De Troyer (1977) and Forrest et al (1978) . Demeclocycline acts by inducing nephrogenic diabetes insipidus (Castell and Sparks, 1965; Roth et al, 1967; Singer and Rotenberg, 1973) , which accounts for the fall in urine sodium concentration and urinary urea-serum ratio in our patients. At a subcellular level there is evidence of impairment of both the generation and action of cyclic adenosine monophosphate (cyclic AMP), the intracellular mediator of vasopressin (Singer and Rotenberg, 1973; Dousa and Wilson, 1974) . The rate of return of the serum sodium to normal appears to be unrelated to fluid intake. Fluid restriction, therefore, may be unnecessary even in the early stages of treatment. As fluid restriction is relatively easy to manage for short periods, however, it may be used in conjunction with demeclocycline during the first few days of treatment. A free fluid intake may then be permitted. It appears from our results that the effects of demeclocycline on the serum sodium are reversible and that cessation of treatment results in a fall in serum sodium to pretreatment levels. Azotaemia has been reported with the use of demeclocycline in congestive heart failure (Cox et al, 1977) and cirrhosis (Carrilho et al, 1977) . Forrest et al (1978) presented data on seven patients and reported a modest rise in blood urea nitrogen. They commented that noteworthy azotaemia was not observed in any of their patients. De Troyer (1977) reported a moderate rise in blood urea and creatinine levels during treatment, but the rise was not statistically significant. Three of seven patients developed a raised urea and two a raised creatinine. In one case there was a renal metastasis and in the second no cause for the impaired renal function was found. A druginduced nephrotoxicity was therefore invoked as a cause of this renal impairment.
In our series of 14 patients both blood urea and creatinine rose significantly on demeclocycline.
The mean blood urea rose to a maximum level of more than three times the pretreatment value. These changes could not be attributed to volume depletion as there was no significant increase in PCV treatment, and in addition there was no relation between fluid intake and rate of rise in blood urea. There was, however, a significant rise in 24-hour urinary urea excretion, probably as a result of the antianabolic effect of demeclocycline (Shils, 1963) . There was also a rise in serum creatinine, although not as pronounced as the rise in urea, and, in the two patients where serial measurements were made, a fall in creatinine clearance. This azotaemia could therefore be attributed to the dual effect of excess urea production and a specific drug-induced nephrotoxicity.
The present study suggests that the adverse effects of demeclocycline on renal function are more important than previously suggested (Forrest et al, 1978) . In four patients the blood urea rose above 20 mmol/l and in two patients the demeclocycline was discontinued as a result (with the redevelopment of hyponatraemia). Forrest et al (1978) used doses of demeclocycline ranging from 600 to 1200 mg daily while De Troyer (1977) , as in our study, used 1200 mg daily for all patients. This higher dose may therefore be associated with an increased likelihood of impaired renal function. The effects of demeclocycline on renal function therefore appear to be both reversible and dose dependent, and it may be worthwhile to treat the condition with an initial daily dose of 1200 mg and, as the electrolytes return to normal, decrease the dose by titrating it against the serum sodium.
In any case, the risk of azotaemia is a small price to pay for ease of patient management, particularly in a terminal illness. 
